Positive interim data in Phase 2 BEHOLD trial investigating UBX1325 in DMO patientsSeptember 10th 2022
12-week interim results of BEHOLD, a proof-of-concept Phase 2a study investigating the candidate UBX1325, provides a positive outlook for a novel senolytic approach for previously-treated patients with diabetic macular oedema.
Fluid monitor utilises AI to identify, localise and quantify retinal fluidSeptember 7th 2022
Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.
Multicentre Phase 3 clinical trial using AI in nAMD identifies, measures fluid volumes in real timeSeptember 6th 2022
According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.
First analysis of gene therapy for RPE65 inherited retinal dystrophies shows good safety, efficacySeptember 3rd 2022
At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.
RGX-314 provided 2-Step or more improvement in diabetic severity in Phase 2 Altitude study analysisSeptember 2nd 2022
The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.
Hair cortisol may act as molecular biomarker for retinitis pigmentosa patientsSeptember 1st 2022
Patients with retinitis pigmentosa experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programmeSeptember 1st 2022
Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.
EURETINA celebrates women in retinaAugust 28th 2022
The stated core foundation of the Women in Retina program is that “the best innovations happen when diverse people with different perspectives collaborate.” The program will help ESRS harness these perspectives and challenge the way things are done and allow for them to be done better.
LIGHTSITE II study: Photobiomodulation treatment improves vision in eyes with dry AMDSeptember 12th 2021
During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.
Exploring the clinical and humanistic burden of geographic atrophySeptember 11th 2021
During a presentation at the EURETINA 2021 Virtual Congress, Dr Daniel Jones discussed GA and emphasized the need for additional study to gain a better understanding of the burden experienced by patients.
Brolucizumab injection improves vision in eyes with neovascular AMDSeptember 11th 2021
In a presentation at the EURETINA 2021 Virtual Congress, Dr Cristina Cristian noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.
Role of anterior vitreous, managing retinal folds in retinal detachment casesSeptember 11th 2021
Dr Grazia Pertile discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
Optogenetic therapy for retinal degeneration shows potential of gene-independent therapeutic strategiesSeptember 10th 2021
During a presentation at the EURETINA 2021 Virtual Congress, Dr José-Alain Sahel explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.